Everett Harris & Co. CA decreased its stake in Pfizer Inc. (NYSE:PFE) by 6.0% during the second quarter, Holdings Channel reports. The firm owned 74,945 shares of the biopharmaceutical company’s stock after selling 4,802 shares during the period. Everett Harris & Co. CA’s holdings in Pfizer were worth $2,639,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stelac Advisory Services LLC bought a new position in shares of Pfizer during the second quarter valued at about $110,000. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the period. Commonwealth Financial Services LLC boosted its stake in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares during the period. Stuart Chaussee & Associates Inc. boosted its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the period. Finally, Jag Capital Management LLC purchased a new stake in shares of Pfizer during the second quarter worth approximately $202,000. Institutional investors own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.694% during trading on Monday, reaching $33.635. 11,679,631 shares of the company were exchanged. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The stock’s 50 day moving average is $34.48 and its 200 day moving average is $34.04. The company has a market capitalization of $204.02 billion, a price-to-earnings ratio of 29.818 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the business earned $0.56 earnings per share. Pfizer’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.54%. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
A number of analysts have commented on PFE shares. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Jefferies Group cut their price objective on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, September 13th. Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a research report on Monday, August 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a research report on Tuesday, August 23rd. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.